lamivudine has been researched along with Angor Pectoris in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adamek, J; Bolewska, B; Cianciara, J; Czajka, B; Gonciarz, Z; Gładysz, A; Juszczyk, J; Król, F; Kryczka, W; Mazur, W; Nazzal, K; Swietek, K | 1 |
1 trial(s) available for lamivudine and Angor Pectoris
| Article | Year |
|---|---|
A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Topics: Abdominal Pain; Adult; Aged; Alanine Transaminase; Angina Pectoris; Antiviral Agents; Biomarkers; Bronchopneumonia; Colitis, Ulcerative; DNA, Viral; Female; Gastrointestinal Diseases; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Lamivudine; Male; Middle Aged; Poland; Reverse Transcriptase Inhibitors; Safety; Urinary Tract Infections; Viral Load; Viremia; Virus Replication | 2002 |